The following is a quick summary of interesting reports in the literature for June 2023.
COVID-19
CNS infection
Alzheimer’s disease
Biomarkers
Headache
Multiple sclerosis
Neurodegenerative disorders
Neuromyelitis optica
Stroke Read More
Latest News
Novel approach to MS therapeutics: anti-CD40L
June 21, 2023CMSC 2023
An emerging therapeutic target of interest is CD40 and its ligand (CD40L), which initially drew attention for their role in activating B cells and macrophages in response to infection (reviewed in Ots et al. Int J Mol Sci 2022;23:4115). Subsequent investigations implicated abnormal CD40 expression in a number of neurological disorders, including multiple sclerosis. Read More
CLINICAL CASES IN MS – A case of worsening mobility during the pandemic
June 13, 2023Click here to watch Dr. Julie Prévost discuss the case and the responses to the survey.
Michelle, 46, is a bank manager who was diagnosed with MS in 1996. She was initially treated with interferon-beta-1a 44 ug. She experienced ongoing clinical and radiological activity and was switched to natalizumab in 2013. She remained stable for seven years. In February 2020, Michelle noted that she used to be able to walk 2 km but could now only manage about 1 km. Her EDSS score showed no change over the past year. EDSS score was 3.0 (motor 2, cerebellar 2, sensory 2). She was started on 4-aminopyridine but obtained no benefit. Read More
Re-evaluating the balance of efficacy and safety with disease-modifying therapies
June 8, 2023Includes data on early use of high-efficacy DMTs, risks of undertreatment of MS, safety issues and de-risking anti-CD20 therapy during long-term use.
16 slides